GlassScriptPhysician profile
Anthony P Chan
NPI 1457449621
$4,091.02
in general payments reported to CMS, 2019-2025
17 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2021: $204 · 2022: $446 · 2023: $809 · 2024: $913 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,209.18 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $646.59 | 2023-2025 | Rinvoq, Linzess, Viberzi |
| Gilead Sciences, INC. | $580.85 | 2019-2024 | |
| Ibsa Pharma INC. | $382.98 | 2022-2024 | Tirosint, Licart, Licart |
| Amgen INC. | $242.93 | 2019-2024 | Repatha |
| Allergan, INC. | $132.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $130.00 | 2022 | |
| Pfizer INC. | $125.00 | 2019 | |
| Madrigal Pharmaceuticals | $120.47 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $120.03 | 2019 | |
| Ardelyx, INC. | $106.88 | 2024-2025 | Ibsrela |
| Olympus America INC. | $80.66 | 2023 | Evis Exera Lll Colonovideoscope |
| Phathom Pharmaceuticals, INC. | $68.60 | 2025 | Voquezna |
| Novo Nordisk INC | $67.08 | 2025 | Wegovy |
| Amarin Pharma, INC. | $43.56 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.48 | 2024 | |
| Aimmune Therapeutics, INC. | $16.31 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.